Affiliation:
1. NHS Northwest London, Brent Integrated Health Board, Wembley Centre for Health and Care London United Kingdom
Abstract
AbstractThe global morbidity, mortality and health economic effects of treating patients with diabetic foot ulcer infections are rapidly growing and have been exacerbated by the problem of antimicrobial resistance. With the world on the cusp of entering the postantibiotic era, alternative antimicrobial strategies are urgently needed. Bacteriophage therapy has demonstrated safety, efficacy and cost‐effectiveness in treating patients with diabetic foot ulcer infections. This review seriously considers the use of bacteriophage therapy in the care of patients with diabetic foot ulcer infections.